Unknown

Dataset Information

0

Salvage systemic therapy for advanced gastric and oesophago-gastric junction adenocarcinoma.

ABSTRACT:

SUBMITTER: Tomita Y 

PROVIDER: S-EPMC8094513 | biostudies-literature |

REPOSITORIES: biostudies-literature

Json Xml

Similar Datasets

Unknown Sequential FDG-PET and induction chemotherapy in locally advanced adenocarcinoma of the Oesophago-gastric junction (AEG): the Heidelberg Imaging program in Cancer of the oesophago-gastric junction during Neoadjuvant treatment: HICON trial.
| S-EPMC3149600 | biostudies-literature
Unknown PET/CT-tailored treatment of locally advanced oesophago-gastric junction adenocarcinoma: a report on the feasibility of the multicenter GastroPET study.
| S-EPMC8753528 | biostudies-literature
Unknown Ramucirumab for advanced gastric cancer or gastro-oesophageal junction adenocarcinoma.
| S-EPMC4622287 | biostudies-literature
Unknown Pembrolizumab for treatment of advanced gastric and gastroesophageal junction adenocarcinoma.
| S-EPMC5827797 | biostudies-literature
Unknown mRNA profiling of the cancer degradome in oesophago-gastric adenocarcinoma.
| S-EPMC3389427 | biostudies-literature
Unknown Positioning of second-line treatment for advanced gastric and gastroesophageal junction adenocarcinoma.
| S-EPMC5224844 | biostudies-literature
Unknown Phase II study of TP300 in patients with advanced gastric or gastro-oesophageal junction adenocarcinoma.
| S-EPMC5057500 | biostudies-literature
Unknown Improved 5-Factor Prognostic Classification of Patients Receiving Salvage Systemic Therapy for Advanced Urothelial Carcinoma.
| S-EPMC5025874 | biostudies-literature
Unknown Ramucirumab combined with FOLFOX as front-line therapy for advanced esophageal, gastroesophageal junction, or gastric adenocarcinoma: a randomized, double-blind, multicenter Phase II trial.
| S-EPMC7360144 | biostudies-literature
Unknown Anti-angiogenic Therapy in Patients with Advanced Gastric and Gastroesophageal Junction Cancer: A Systematic Review.
| S-EPMC5654167 | biostudies-literature